Patient persistency with pharmacotherapy in the management of glaucoma.

G. Reardon, Gail Schwartz, E. Mozaffari

Research output: Contribution to journalArticle

Abstract

PURPOSE: To evaluate persistency with monotherapy in the treatment of glaucoma in patients new to pharmacological management. METHODS: This population-based, retrospective cohort study, using managed care administrative claims data, included patients who were 20 years of age and older and who initiated monotherapy with betaxolol, brimonidine, dorzolamide, latanoprost, or timolol between May 1999 and January 2001. Follow-up continued through January 31, 2001, and prescription refill records for all ocular hypotensive medications were extracted for the full 21-month study period. The primary outcome measures were discontinuation and change (switching/adding on) of the index ocular hypotensive medication. Rates of discontinuation and discontinuation/change were compared using Cox regression methods; survival curves were generated. RESULTS: In all, 14,539 patients were prescribed any ocular hypotensive drug during the study period, and 2850 patients met all inclusion criteria. Patients treated with betaxolol, brimonidine, dorzolamide, or timolol were significantly (p < 0.05) more likely to discontinue and to discontinue/change the index therapy than were those treated with latanoprost. Results were confirmed in analyses adjusted for age and sex. CONCLUSIONS: Patients initially treated with latanoprost monotherapy are more persistent than those who begin treatment with beta-blockers, brimonidine, or the carbonic anhydrase inhibitor dorzolamide. Greater persistency with an initial ocular hypotensive therapy may improve health outcomes and reduce long-term costs to patients and health plans by limiting the increased resource use associated with discontinuations or changes in therapy.

Original languageEnglish (US)
JournalEuropean Journal of Ophthalmology
Volume13 Suppl 4
StatePublished - Jul 1 2003
Externally publishedYes

Fingerprint

latanoprost
Glaucoma
dorzolamide
Drug Therapy
Betaxolol
Timolol
Carbonic Anhydrase Inhibitors
Therapeutics
Health
Managed Care Programs
Prescriptions
Cohort Studies
Retrospective Studies
Outcome Assessment (Health Care)
Pharmacology
Costs and Cost Analysis
Survival
Pharmaceutical Preparations
Population
Brimonidine Tartrate

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Patient persistency with pharmacotherapy in the management of glaucoma. / Reardon, G.; Schwartz, Gail; Mozaffari, E.

In: European Journal of Ophthalmology, Vol. 13 Suppl 4, 01.07.2003.

Research output: Contribution to journalArticle

@article{08de122984db4f3e8161847b9fe55152,
title = "Patient persistency with pharmacotherapy in the management of glaucoma.",
abstract = "PURPOSE: To evaluate persistency with monotherapy in the treatment of glaucoma in patients new to pharmacological management. METHODS: This population-based, retrospective cohort study, using managed care administrative claims data, included patients who were 20 years of age and older and who initiated monotherapy with betaxolol, brimonidine, dorzolamide, latanoprost, or timolol between May 1999 and January 2001. Follow-up continued through January 31, 2001, and prescription refill records for all ocular hypotensive medications were extracted for the full 21-month study period. The primary outcome measures were discontinuation and change (switching/adding on) of the index ocular hypotensive medication. Rates of discontinuation and discontinuation/change were compared using Cox regression methods; survival curves were generated. RESULTS: In all, 14,539 patients were prescribed any ocular hypotensive drug during the study period, and 2850 patients met all inclusion criteria. Patients treated with betaxolol, brimonidine, dorzolamide, or timolol were significantly (p < 0.05) more likely to discontinue and to discontinue/change the index therapy than were those treated with latanoprost. Results were confirmed in analyses adjusted for age and sex. CONCLUSIONS: Patients initially treated with latanoprost monotherapy are more persistent than those who begin treatment with beta-blockers, brimonidine, or the carbonic anhydrase inhibitor dorzolamide. Greater persistency with an initial ocular hypotensive therapy may improve health outcomes and reduce long-term costs to patients and health plans by limiting the increased resource use associated with discontinuations or changes in therapy.",
author = "G. Reardon and Gail Schwartz and E. Mozaffari",
year = "2003",
month = "7",
day = "1",
language = "English (US)",
volume = "13 Suppl 4",
journal = "European Journal of Ophthalmology",
issn = "1120-6721",
publisher = "Wichtig Publishing",

}

TY - JOUR

T1 - Patient persistency with pharmacotherapy in the management of glaucoma.

AU - Reardon, G.

AU - Schwartz, Gail

AU - Mozaffari, E.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - PURPOSE: To evaluate persistency with monotherapy in the treatment of glaucoma in patients new to pharmacological management. METHODS: This population-based, retrospective cohort study, using managed care administrative claims data, included patients who were 20 years of age and older and who initiated monotherapy with betaxolol, brimonidine, dorzolamide, latanoprost, or timolol between May 1999 and January 2001. Follow-up continued through January 31, 2001, and prescription refill records for all ocular hypotensive medications were extracted for the full 21-month study period. The primary outcome measures were discontinuation and change (switching/adding on) of the index ocular hypotensive medication. Rates of discontinuation and discontinuation/change were compared using Cox regression methods; survival curves were generated. RESULTS: In all, 14,539 patients were prescribed any ocular hypotensive drug during the study period, and 2850 patients met all inclusion criteria. Patients treated with betaxolol, brimonidine, dorzolamide, or timolol were significantly (p < 0.05) more likely to discontinue and to discontinue/change the index therapy than were those treated with latanoprost. Results were confirmed in analyses adjusted for age and sex. CONCLUSIONS: Patients initially treated with latanoprost monotherapy are more persistent than those who begin treatment with beta-blockers, brimonidine, or the carbonic anhydrase inhibitor dorzolamide. Greater persistency with an initial ocular hypotensive therapy may improve health outcomes and reduce long-term costs to patients and health plans by limiting the increased resource use associated with discontinuations or changes in therapy.

AB - PURPOSE: To evaluate persistency with monotherapy in the treatment of glaucoma in patients new to pharmacological management. METHODS: This population-based, retrospective cohort study, using managed care administrative claims data, included patients who were 20 years of age and older and who initiated monotherapy with betaxolol, brimonidine, dorzolamide, latanoprost, or timolol between May 1999 and January 2001. Follow-up continued through January 31, 2001, and prescription refill records for all ocular hypotensive medications were extracted for the full 21-month study period. The primary outcome measures were discontinuation and change (switching/adding on) of the index ocular hypotensive medication. Rates of discontinuation and discontinuation/change were compared using Cox regression methods; survival curves were generated. RESULTS: In all, 14,539 patients were prescribed any ocular hypotensive drug during the study period, and 2850 patients met all inclusion criteria. Patients treated with betaxolol, brimonidine, dorzolamide, or timolol were significantly (p < 0.05) more likely to discontinue and to discontinue/change the index therapy than were those treated with latanoprost. Results were confirmed in analyses adjusted for age and sex. CONCLUSIONS: Patients initially treated with latanoprost monotherapy are more persistent than those who begin treatment with beta-blockers, brimonidine, or the carbonic anhydrase inhibitor dorzolamide. Greater persistency with an initial ocular hypotensive therapy may improve health outcomes and reduce long-term costs to patients and health plans by limiting the increased resource use associated with discontinuations or changes in therapy.

UR - http://www.scopus.com/inward/record.url?scp=0642343075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0642343075&partnerID=8YFLogxK

M3 - Article

C2 - 12948052

AN - SCOPUS:0642343075

VL - 13 Suppl 4

JO - European Journal of Ophthalmology

JF - European Journal of Ophthalmology

SN - 1120-6721

ER -